|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
INCREASED SEDATIVE EFFECT
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|